Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rozanolixizumab - UCB

Next Previous
X
Search
Drug Profile

Rozanolixizumab - UCB

Alternative Names: Rozanolixizumab-noli; RYSTIGGO; UCB-7665

Latest Information Update: 12 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Neonatal Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myasthenia gravis
  • Phase III CNS disorders; Idiopathic thrombocytopenic purpura
  • Phase II Chronic inflammatory demyelinating polyradiculoneuropathy; Encephalitis; Fibromyalgia

Most Recent Events

  • 06 Aug 2024 UCB Biopharma plans a phase III trial for Myasthenia gravis (In adolescents, In adults, In the elderly) (SC) in October 2024 (NCT06540144)
  • 09 Jul 2024 UCB Biopharma completes a phase-II trial in Fibromyalgia in United Kingdom (unspecified route) (EudraCT-2022-001523-32) (NCT05643794)
  • 14 Jun 2024 Phase-II/III clinical trials in Myasthenia gravis (In adolescents, In children) in Poland, Italy, USA (SC) (NCT06149559)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top